Washington, D.C. | January 29, 2026 — The U.S. International Trade Commission (USITC) has formally instituted a Section 337 investigation (Inv. No. 337-TA-1483) into the importation and sale of certain medical imaging devices, following a complaint alleging patent infringement. The action, initiated at the request of MolecuLight Inc. and MolecuLight Corp., underscores the growing intersection of medical device innovation, intellectual property protection, and international trade enforcement within the regulated healthcare technology landscape.
Science Significance
From a scientific and technological standpoint, the investigation centers on advanced medical imaging devices used in clinical and care settings. Such devices often rely on proprietary optical, imaging, and analytical technologies designed to enhance diagnostic accuracy and clinical decision-making. Protecting innovation in this space is critical, as imaging technologies directly influence care quality, workflow efficiency, and clinical outcomes. The Section 337 complaint highlights how scientific differentiation and patented technologies are increasingly central to competitive positioning in MedTech, particularly as imaging solutions evolve rapidly and global suppliers enter the U.S. market.
Regulatory Significance
Regulatorily, the institution of a Section 337 investigation reflects the USITC’s role as a key enforcement body safeguarding U.S. intellectual property rights at the border. Section 337 of the Tariff Act of 1930 provides remedies against unfair trade practices, including the importation of products that infringe valid U.S. patents. The USITC has not yet ruled on the merits of the allegations; however, the investigation triggers a formal adjudicative process, including assignment to an Administrative Law Judge (ALJ), evidentiary hearings, and an initial determination subject to Commission review. Potential remedies include limited exclusion orders and cease-and-desist orders, which can have immediate regulatory and market impact once issued.
Business Significance
Advertisement
For the medical imaging industry, the investigation carries substantial commercial and competitive implications. The respondents identified—Kent Imaging Inc. and Adiuvo Diagnostics Pvt. Ltd.—face the risk of import restrictions or sales limitations in the U.S. market if a violation is ultimately found. For complainants MolecuLight, the action represents a strategic effort to defend proprietary technology and market position. More broadly, the case signals to MedTech companies that robust IP strategies and compliance with U.S. trade law are essential as globalization accelerates device manufacturing and distribution.
Patients’ Significance
While legal in nature, the investigation has downstream implications for patients and healthcare providers. Medical imaging devices play a crucial role in diagnosis, monitoring, and treatment decisions, and market disruptions—such as product exclusions—can influence device availability, pricing, and innovation incentives. At the same time, strong IP enforcement supports continued investment in research and development, helping ensure that patients benefit from validated, high-quality, and innovative technologies that meet regulatory and clinical standards.
Policy Significance
At the policy level, the case highlights ongoing efforts by the U.S. government to balance open trade with protection of domestic innovation. Section 337 investigations are a key policy tool to deter unfair trade practices while maintaining confidence in the U.S. intellectual property system. The statutory framework also includes a 60-day presidential review period, during which the U.S. Trade Representative may disapprove remedial orders for policy reasons, reflecting broader considerations such as public health, competition, and supply chain resilience.
Overall, the USITC’s decision to institute a Section 337 investigation into certain medical imaging devices underscores the increasing importance of intellectual property enforcement in the MedTech sector. As imaging technologies become more sophisticated and globally sourced, regulatory scrutiny at the intersection of science, trade, and compliance is likely to intensify. For the cGxP.wire audience, the case illustrates how government action, regulatory process, and innovation protection collectively shape the future of regulated healthcare technologies.
Source: U.S. International Trade Commission press release
